Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 500 participants.
Also called NCT04943692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 500 participants
- Registry
-
NCT04943692
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Suspended
Technical summary
Registry record NCT04943692. Randomized; double masking; primary purpose treatment. Start 2021-08 (anticipated); primary completion 2021-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
- Acronym
- COMETII
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin glycinate
- Intervention (Drug)
- Metformin Hydrochloride
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.
Record details
- Record id
cardio:ct-nct04943692- Content hash
e5df0ca0518270b3df3c0b7ae5bf14d8ef93328fed8f2abc653374e58b8fea64